Alzheimer Disease

Lithium: what’s its history and where do we still need more information?

What are the available and upcoming AD treatments and how can you utilize them to best serve your patients?

The experts weighed in on a wide variety of psychiatric issues for the January 2023 issue of Psychiatric Times.

Alzheimer disease research may offer the key to effective treatment for former athletes.

From evidence-based novel therapies for bipolar depression to potential indicators of early-stage Alzheimer disease, here are highlights from the week in Psychiatric Times.

New research finds that a urine test for formic acid could detect early-stage Alzheimer disease.

From the cross-cultural dimensions of psychosis to the economic burden of schizophrenia, here are highlights from the week in Psychiatric Times.

Results show comparisons between intranasal and intracerebroventricular distribution of an oxytocin derivative.

Can Alzheimer disease research offer the key to effective treatment?

Alzheimer disease psychosis treatment pimavanserin receives Complete Response Letter from the FDA.

Is our research about Alzheimer disease wrong?

Study shows promising results for early detection and prevention efforts.

Top-line data for study is expected in late 2022, early 2023.

Compelling new book discusses love, Alzheimer disease, and medical aid in dying.

Individuals with depression may be at a greater risk to develop late-onset Alzheimer disease, but a new study suggests depression onset may help predict Alzheimer disease.

How can you communicate the diagnosis in a way that relieves suffering and helps patients and their caregivers prepare for the future?

This donepezil transdermal system helps with the treatment on mild, moderate, or severe dementia of the Alzheimer type.

Research also finds surprising results in patients with bipolar affective disorder.

The American Academy of Neurology issued a position statement for mental health professionals, warning them to carefully discuss the benefits and known harms of aducanumab.

A new study finds amyloid plaques accelerate the breakup of neurotransmitters, worsening neurodegenerative diseases like Alzheimer disease.

More potential good news for treating Alzheimer disease, as an 18-month open-label extension for lecanemab allows for its breakthrough status.

Apathy occurs throughout the spectrum of neurocognitive disorders, but it is easy to mistake for other conditions, like depression. How can clinicians identify apathy, and treat it?

Following criticism for its wide-labeled June approval, the FDA has decided to narrow the patient recommendation for aducanumab.

How can volunteering to play video games help brain research?

Donanemab for the treatment of Alzheimer disease has received Breakthrough Therapy designation from the FDA.

This one-of-a-kind Alzheimer disease treatment targets the amyloid beta plaques in the brain, potentially slowing cognitive decline.

Gene expressions in microglia cells may explain why some of them are ineffective and allow dementia to progress.

This monoclonal antibody showed significant slowing of decline in patients with Alzheimer disease.

Aducanumab is named 1 of the 5 “Drugs to Watch” for 2021.

A study on a new Alzheimer disease vaccine lacks concrete numbers.